Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-10-23
2007-10-23
Campbell, Bruce R. (Department: 1648)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387500, C530S388100, C530S388200, C530S388230, C530S350000, C530S389100
Reexamination Certificate
active
10625204
ABSTRACT:
The present invention relates to the use of a compound that binds to a C-type lectin on the surface of a dendritic cell, in the preparation of a composition for modulating, in particular reducing, the immune response in an animal, in particular a human or another mammal. The composition in particular modulates the interactions between a dendritic cell and a T-cell, more specifically between a C-type lectin on the surface of a dendritic cell and an ICAM receptor on the surface of a T-cell. The compositions can be used for preventing/inhibiting immune responses to specific antigens, for inducing tolerance, for immunotherapy, for immunosuppression, for the treatment of autoimmune diseases, and the treatment of allergy. The compound that binds to a C-type lectin is preferably chosen from mannose, fucose, plant lectins, antibiotics, sugars, proteins or antibodies against C-type lectins. The invention also relates to such antibodies.
REFERENCES:
patent: 6605279 (2003-08-01), Freeman et al.
patent: 2003/0232745 (2003-12-01), Olson et al.
patent: WO93/01820 (1993-02-01), None
patent: WO96/23882 (1996-08-01), None
patent: WO98/02456 (1998-01-01), None
patent: WO98/02456 (1998-01-01), None
patent: WO98/28332 (1998-07-01), None
patent: WO98/28332 (1998-07-01), None
patent: WO98/41633 (1998-09-01), None
patent: WO98/49306 (1998-11-01), None
patent: WO98/55508 (1998-12-01), None
patent: WO98/55508 (1998-12-01), None
Eck et al (1999) Eur. J. Biochem. 264: 775-784.
Yan et al (1999) J. Immunol. 163(6): 3045-52.
Curtis BM et al., “Sequence and expression of a membrane-associated C-type lectin that exhibits CD4-independent binding of human immunodeficiency virus envelope glycoprotein gp120”, Proc. Natl. Acad. Sci. USA 89:8356-8360 (1992).
Tsunetsugu-Yokota Y et al., “Efficient Virus Transmission from Dendritic Cells to CD4+ T Cells in Response to Antigen Depends on Close Contact through Adhesion Molecules”, Virology 239:259-268 (1997).
Zoeteweij JP and Blauvelt A, “HIV-Dendritic Cell Interactions Promote Efficient Viral Infection of T Cells”, J. Biomed. Sci. 5:253-259 (1998).
Manca F et al., “Dendritic Cells Are Potent Antigen-Presenting Cells for In Vitro Induction of Primary Human CD4+ T-Cell Lines Specific for HIV gp120”, Journal of Acquired Immune Deficiency Syndromes 7:15-23 (1994).
Knight SC and Patterson S, “Bone Marrow-Derived Dendritic Cells, Infection with Human Immunodeficiency Virus, and Immunopathology”, Annu. Rev. Immunol. 15:593-615 (1997).
GENBANK Accession No. AB015629 including updates of Apr. 17, 1999; Apr. 20, 1999; Apr. 20, 1999 (later time); Jul. 26, 2001; and Jul. 23, 2002.
Amersdorfer et al.,Infection and Immunity, 65, pp. 3743-3752 (1997).
Andre et al.,Journal of Virology, 72(2), pp. 1497-1503 (1998).
Baribaud, Frederic, et al., “Functional and Antigenic Characterization of Human, Rhesus Macaque, Pigtailed Macaque, and Murine DC-SIGN,”Journal of Virology, 75(21), pp. 10281-10289 (2001).
Kataoka et al.,Cancer Research, 38(5), pp. 1202-1207 (1987)—Abstract only from Biosis database.
Cohen,Science, 287, p. 1567 (2000).
Engering, Anneke, et al., “The Dendritic Cell-Specific Adhesion Receptor DC-SIGN Internalizes Antigen for Presentation to T Cells,”J. of Immun., 168, pp. 2118-2126 (2000).
Feinberg, Hadar, et al., “Structural Basis for Selective Recognition of Oligosaccharides by DC-SIGN and SC-SIGNR,”Science, 294, pp. 2163-2166 (2001) (with Supplementary Material published electronically on theSciencewebsite, 6 pgs.).
Geijtenbeek, Teunis, B.H., et al., “Identification of DC-SIGN, a Novel Dendritic Cell-Specific ICAM-3 Receptor that Supports Primary Immune Responses,”Cell, 100, pp. 575-585 (2000).
Geijtenbeek, Teunis, B.H., et al.,Cell, 100, pp. 587-597 (2000).
Geijtenbeek, et al., “Identification of Different Binding Sites in the Dendritic Cell-Specific Receptor DC-SIGN for Intercellular Adhesion Molecule 3 and HIV-1,”J. Biol. Chem., 227(13), pp. 11314-11320 (2002).
Gruber, Andreas, et al., “Functional Aspects of Binding of Monoclonal Antibody DCN46 to DC-SIGN on Dendritic Cells,”Immunology Letters, 84, pp. 103-108 (2002).
Harlow and Lane, Antibodies: A Laboratory Manual, 1988 Cold Spring Harbor Laboratory, pp. 141-142.
Janeway, Charles, A., Jr., et al.,Immunobiology, (5th ed.), Garland Publishing, New York, p. 691 (2001).
Pohlmann, Stefan, et al., “DC-SIGN Interactions with Human Immunodeficiency Virus Type 1 and 2 and Simian Immunodeficiency Virus,”J. of Virology, 75(10), pp. 4664-4672 (2001).
Steinman,Cell, 287, pp. 491-494 (2000).
Vakeva, Antti, P., et al., “Myocardial Infarction and Apoptosis After Myocardial Ischemia and Reperfusion,”Circulation, 97, pp. 2259-2267 (1998).
Woodle, E.S., et al.,Translplantation, 68, pp. 608-616 (1999).
FDA Approves Second Indication for Monolclonal Antibody, Jun. 28, 1993, printed on Nov. 12, 2004 from http:/www.fda.gov/bbs/topics/ANSWERS/ANS00506.html, Jun. 28, 1993.
Product Information for Affinity Purified anti-human CD209 (DC-SIGN) antibody, from eBioscience, printed on Jan. 5, 2004 from http://www.ebioscience.com/ebioscience/specs/antibody—14/14-2099.htm.
Product information for CDN46, Purified Mouse Anti-Human Monoclonal Antibody, BD PharMingen Technical Data Sheet, BD Biosciences Product Information Sheet, Catalog No. 551186, May 1, 2001.
Package insert for Orthoclone OKT3 Sterile Solution (murumonab-CD3) from Ortho Biotech Products LP, Raritan, NJ, Revised Mar. 2001.
Sequence Alignment of Curtis et al., PNAS 89: 8356-8360 (1992) with SEQ ID No. 2 from U.S. Appl. No. 09/719,961.
Figdor Carl Gustav
Geijtenbeek Teunis Bernard Herman
Kooyk Yvette Van
Torensma Ruurd
Campbell Bruce R.
Horning Michelle
Katholieke Universiteit Nijmegen
Ropes & Gray LLP
LandOfFree
Composition and method for modulating dendritic cell-T cell... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition and method for modulating dendritic cell-T cell..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition and method for modulating dendritic cell-T cell... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3902417